Harnessing the power of botanically derived therapeutics
We develop innovative pharmaceutical grade DMT-based medicines and therapies aiming to transform the lives of those facing some of the most prolific and insidious mental illnesses
Our Story
Our founding team are some of the foremost experts on botanical psychedelic medicines including having conducted the world’s largest study into the effects of Ayahuasca.
After seeing the amazing potential of botanical psychedelic compounds we were drawn to finding a way to develop clinical treatments for the millions of people that suffer with mental illnesses each day.
To this end, our initial product utilises a purifed plant-based DMT medicine produced via modern science. This is combined with our taliored psychotherapeutic model, to create a highly-effective transformative treatment for a range of mental illnesses
We are on a mission to not just treat symptoms of mental illness, but to improve the quality of life for the hundreds of millions of sufferers around the world
Our Mission
Our Path Forward
To date we have:
Identified plant sources of our target compounds that can be grown and harvested at commercial scale
Developed unique extraction and purification techniques with CSIRO (Australia) to create a standardise pharmaceutical grade extract
Created a tailored psychological therapeutic treatment model with digital therapeutics support
Phase 1 clinical trial commenced (for completion in December 2023)
Raised $4.5m in Venture Capital alongside a $2m MRFF grant to complete our Phase 2 clinical trials
If you’d like to join in the Psychae journey, please contact us below
Meet the Team
-
Daniel Perkins
CO-CEO & CO-FOUNDER
-
Jerome Sarris
CO-CEO & CO-FOUNDER
-
Andrew McLean
Director
-
Bec Kannourakis
STRATEGY AND PLANNING
-
Andreas Halman
NEUROSCIENCE AND BIOINFORMATICS
Follow Our Journey.
If you want to get regular updates on our progress, please join our mailing list below.